The Navigation Model of Therapy: Why Awareness Changes Everything
November 16, 2025
Brand Name :
Zoladex
(United States) [Available]Synonyms :
Goserelin
Class :
Antineoplastics and GnRH Antagonist
Dosage Forms & Strengths  Â
Implant  Â
3.6mg  Â
10.8mg   Â
Monthly implant: 3.6 mg subcutaneously placed in the upper abdominal wall for every 28days
3-month implant: 10.8 mg subcutaneously placed in the upper abdominal wall for every 12week
Long term treatment intended for unless clinically inappropriate
3.6
mg
Subcutaneous (SC)
28
days
which is placed in the upper abdominal wall
Long term treatment intended for unless clinically inappropriate
3.6 mg subcutaneously placed in the upper abdominal wall for every 28days The maximum duration of the treatment is six months
when both drugs are combined, there may be increased toxicity of amiodarone by QTC interval  
when both drugs are combined, there may be increased toxicity of anagrelide by QTC interval  
when both drugs are combined, there may be increased toxicity of arsenic trioxide by QTC interval  
when both drugs are combined, there may be increased toxicity of artemether by QTC interval  
when both drugs are combined, there may be increased toxicity of citalopram by QTC interval  
when both drugs are combined, there may be increased toxicity of disopyramide by QTC interval  
when both drugs are combined, there may be an increase in qtc interval and toxicity of nilotinib  
when both drugs are combined, there may be an increased QTC interval  
when both drugs are combined, there may be an increased QTC interval  
when both drugs are combined, there may be an increased QTC interval  
when both drugs are combined, there may be an increased QTC interval  
when both drugs are combined, there may be an increased QTC interval   goser
when both drugs are combined, there may be an increased QTC interval  
when both drugs are combined, there may be an increased QTC interval  
when both drugs are combined, there may be an increased QTC interval  
QTc interval is increased both by lenvatinib and goserelin
when both drugs are combined, there may be an increased QTC interval  
when both drugs are combined, there may be an increased QTC interval  
when both drugs are combined, there may be an increased QTC interval  
when both drugs are combined, there may be an increased QTC interval  
when both drugs are combined, there may be an increased QTC interval  
when both drugs are combined, there may be an increased QTC interval  
when both drugs are combined, there may be an increased QTC interval  
when both drugs are combined, there may be an increased QTC interval  
when both drugs are combined, there may be an increased QTC interval 
It may diminish the effects when combined with metformin by pharmacodynamic antagonism
osimertinib and goserelin, when used simultaneously, increase the QTc interval
One artificial decapeptide analogue of LHRH is goserelin.Â
When goserelin is taken in its biodegradable form, it effectively inhibits the release of pituitary gonadotropin. Â
Long-term suppression of serum testosterone and LH levels is the outcome.Â
Adverse drug reactions:  Â
Frequency defined  Â
>10%  Â
Acne   Â
Diarrhea   Â
Breast atrophy   Â
Flushing   Â
Vaginitis   Â
Hot flashes   Â
Reduced libido   Â
Mood swings   Â
Depression  Â
Sweating  Â
Headache  Â
Peripheral edema   Â
Erectile dysfunction  Â
Seborrhea   Â
Tumor flare   Â
Sexual dysfunction  Â
Pain   Â
UTI  Â
1-10%  Â
Nausea  Â
Lethargy   Â
Rash   Â
COPD  Â
Congestive heart failure  Â
Cerebrovascular accident   Â
Depression   Â
Immune hypersensitivity reaction  Â
Renal impairment   Â
Headache   Â
Frequency Not Defined  Â
Asthenia  Â
Breast changes  Â
Cystitis  Â
Dyspareunia  Â
Dysmenorrhea  Â
Hypercalcemia  Â
Hirsutism Â
Â
None
Contraindication:Â
HypersensitivityÂ
Caution:Â
HypercalcemiaÂ
Women of childbearing potential and pregnancyÂ
Tumor flareÂ
Hyperglycemia and diabetesÂ
Cardiovascular diseasesÂ
Pregnancy warnings:   Â
Breastfeeding warnings:Â
Pregnancy Categories:     Â
Â
Analog of gonadotropin-releasing hormone (LHRH); long-term goserelin stimulation suppresses serum levels of FSH and LH.Â
These trials used a single 250µg (aqueous solution) dosage of goserelin as well as one or more subcutaneous 3.6 mg depot doses.Â
Goserelin is available as a subcutaneous implant.Â
It is subcutaneous injection into the anterior abdominal wall preferably below the navel using a pre-filled syringe with a special delivery system (implant needle).Â
Administer at a 90-degree angle into the subcutaneous tissue of the lower abdomen.Â
Once inserted, the biodegradable implant slowly releases goserelin over time.Â
Patient information leafletÂ
Generic Name: GoserelinÂ
Why do we use Goserelin? Â
Goserelin is indicated in combination with flutamide for the management of locally confined carcinoma of the prostateÂ
It is used in palliative treatment of advanced carcinoma of the prostate.Â
It is also used in the treatment of advanced breast cancer in pre- and perimenopausal women.Â